Sanofi funds AlphaDetect to expand Alpha-1 testing for over 90% undiagnosed patients
Sanofi has become an inaugural industry sponsor of AlphaDetect, providing funding to expand Alpha-1 antitrypsin deficiency detection tools and provider education across healthcare systems. This support aims to address the more than 90% of undiagnosed Alpha-1 patients and drive routine testing in individuals with COPD, treatment-resistant asthma or unexplained liver disease.
1. Sanofi Launches AlphaDetect Sponsorship
Sanofi has joined AlphaDetect as an inaugural industry sponsor, committing financial and strategic support to accelerate detection of Alpha-1 antitrypsin deficiency. The funding will bolster provider education programs and scale proven testing protocols within clinical practices across multiple health systems.
2. Tackling Severe Underdiagnosis
Alpha-1 remains undiagnosed in over 90% of affected individuals despite guidelines calling for testing in all COPD, treatment-resistant asthma and unexplained liver disease cases. AlphaDetect’s expanded toolkit aims to overcome awareness barriers and integrate routine screening into standard care pathways.
3. Strategic Fit in Sanofi’s Rare Disease Efforts
The sponsorship aligns with Sanofi’s broader rare disease strategy, reinforcing its commitment to early diagnosis and patient support. By partnering with AlphaDetect, Sanofi seeks to strengthen its medical affairs capabilities and enhance long-term outcomes for patients at genetic risk.